olivLaw · US equity research
REGENXBIO Inc. RGNX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
At the close of 04 Nov 2026, REGENXBIO Inc. (RGNX) stock was 7.71 USD (+1.05% on the day), with market capitalisation 509.0 m USD, beta 1.83, 52-week range 5.65–15.98 USD. Latest reported quarter (Q2 2026): revenue of 108.0 m USD (+405.7% YoY), net income of 22.7 m USD, diluted EPS 0.43 USD.
Data as of · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 54.1
- neutral
- Bollinger (20, 2)
- 6.42 – 8.10
- in the upper half of the band · %B 0.77 · band width 23.1%
- SMA 50 / 200
- 7.88 / 9.08
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.14 / -0.27
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −0.6% | −1.1% | +0.5 pp | — |
| 3 months | −26.6% | −0.5% | −26.1 pp | — |
| 6 months | −24.6% | +4.4% | −29.0 pp | — |
| Year to date | −46.5% | +12.3% | −58.8 pp | — |
| 1 year | −33.3% | +13.5% | −46.8 pp | +8.1% |
| 3 years | −49.7% | +76.4% | −126.1 pp | +3.1% |
| 5 years | −80.3% | +63.7% | −143.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.2 m | 21.2 m | 89.0 m | 21.4 m | 29.7 m | 30.3 m | 6.4 m | 108.0 m |
| Cost of revenue | 12.4 m | 6.3 m | — | — | — | — | — | — |
| Research & development | 54.4 m | 50.4 m | 53.1 m | 59.5 m | 56.1 m | 59.6 m | 57.3 m | 56.1 m |
| Operating income | -62.1 m | -51.4 m | 12.1 m | -63.3 m | -52.4 m | -57.6 m | -83.4 m | 29.3 m |
| Depreciation & amortisation | 4.0 m ≈ | 4.0 m | 4.0 m | 3.9 m ≈ | 3.9 m ≈ | 3.9 m | 3.9 m | 3.8 m ≈ |
| Interest expense | 820.0 k | 9.4 m | 8.6 m | 11.0 m | 13.2 m | 12.3 m | 8.7 m | 7.8 m |
| Net income | -59.6 m | -51.2 m | 6.1 m | -70.9 m | -61.9 m | -67.1 m | -90.1 m | 22.7 m |
| Diluted EPS | -1.17 | -1.01 ≈ | 0.12 | -1.38 | -1.20 | -1.30 ≈ | -1.72 | 0.43 |
| Operating cash flow | -40.5 m ≈ | -31.6 m | 33.6 m | -49.3 m ≈ | -56.0 m ≈ | -52.3 m | -76.2 m | -62.2 m ≈ |
| Capex | 326.0 k ≈ | 1.1 m | 1.0 m | 391.0 k ≈ | 491.0 k ≈ | 508.0 k | 1.2 m | 760.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218.5 m | 35.2 m | 154.6 m | 470.3 m | 112.7 m | 90.2 m | 83.3 m | 170.4 m |
| Revenue YoY | +2,002.4% | −83.9% | +338.7% | +204.3% | −76.0% | −19.9% | −7.7% | +104.5% |
| Net income | 99.9 m | -94.7 m | -111.3 m | 127.8 m | -280.3 m | -263.5 m | -227.1 m | -193.9 m |
| Net income YoY | unavailable | −194.8% | unavailable | unavailable | −319.3% | unavailable | unavailable | unavailable |
| Diluted EPS | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 |
| Diluted EPS YoY | unavailable | −194.5% | unavailable | unavailable | −323.4% | unavailable | unavailable | unavailable |
| net % | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| Free cash flow | 91.4 m | -119.4 m | -80.9 m | 134.7 m | -238.2 m | -228.4 m | -175.6 m | -126.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 34.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 102.7 m USD
- Total assets
- 453.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 2.38x
- ROE
- -107.0%
- ROA
- -42.2%
- FCF margin
- -74.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 154.6 m | 470.3 m | 112.7 m | 90.2 m | 83.3 m | 170.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Cost of revenue | 35.7 m | 51.8 m | 54.5 m | 37.2 m | 33.6 m | — | SEC (XBRL)· 13 Mar 2025verified |
| Gross profit | 118.9 m ≈ | 418.5 m ≈ | 58.2 m ≈ | 53.0 m ≈ | 49.8 m ≈ | — | SEC (XBRL)· 13 Mar 2025derived |
| Research & development | 166.3 m | 181.4 m | 242.5 m | 232.3 m | 208.5 m | 228.3 m | SEC (XBRL)· 05 Mar 2026verified |
| Operating income | -119.2 m | 160.0 m | -262.9 m | -268.1 m | -233.3 m | -161.2 m | SEC (XBRL)· 05 Mar 2026verified |
| Depreciation & amortisation | 8.4 m | 9.6 m | 12.9 m | 17.3 m | 16.2 m | 15.6 m | SEC (XBRL)· 05 Mar 2026verified |
| EBITDA | -110.8 m ≈ | 169.5 m ≈ | -250.0 m ≈ | -250.8 m ≈ | -217.1 m ≈ | -145.6 m ≈ | SEC (XBRL)· 05 Mar 2026derived |
| Interest expense | 771.0 k | 26.3 m | 23.3 m | 6.9 m | 12.7 m | 45.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Pre-tax income | -106.0 m | 141.2 m | -280.4 m | -263.6 m | -227.1 m | -193.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Income tax | 5.2 m | 13.4 m | -84.0 k | -152.0 k | 0 | 0 | SEC (XBRL)· 05 Mar 2026verified |
| Net income | -111.3 m | 127.8 m | -280.3 m | -263.5 m | -227.1 m | -193.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Diluted EPS | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 | SEC (XBRL)· 05 Mar 2026verified |
| Weighted average diluted shares | 37.3 m | 43.9 m | 43.2 m | 43.7 m | 49.5 m | 51.6 m | SEC (XBRL)· 05 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 338.4 m | 345.2 m | 97.0 m | 34.5 m | 57.5 m | 34.5 m | SEC (XBRL)· 05 Mar 2026verified |
| Receivables | 43.0 m | 32.4 m | 28.1 m | 24.8 m | 20.5 m | 26.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Current assets | 531.2 m | 518.8 m | 416.0 m | 335.0 m | 278.0 m | 281.3 m | SEC (XBRL)· 05 Mar 2026verified |
| Property, plant & equipment, net | 56.5 m | 131.5 m | 141.7 m | 132.1 m | 117.6 m | 104.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Total assets | 708.2 m | 1.1 bn | 833.3 m | 574.0 m | 466.0 m | 453.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Accounts payable | 10.6 m | 11.4 m | 27.2 m | 22.8 m | 22.8 m | 21.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Current liabilities | 81.4 m | 130.5 m | 130.4 m | 130.3 m | 103.2 m | 118.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Total liabilities | 330.4 m | 349.6 m | 317.1 m | 262.2 m | 206.3 m | 350.3 m | SEC (XBRL)· 05 Mar 2026verified |
| Equity | 377.8 m † | 764.3 m † | 516.2 m † | 311.7 m † | 259.7 m † | 102.7 m † | SEC (XBRL)· 05 Mar 2026verified |
| Shares outstanding at year end | — | 42.9 m | — | — | — | — | SEC (XBRL)· 01 Mar 2022verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -54.1 m | 218.9 m | -207.5 m | -218.4 m | -173.1 m | -124.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Capex | 26.9 m | 84.2 m | 30.7 m | 10.0 m | 2.4 m | 2.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Free cash flow | -80.9 m ≈ | 134.7 m ≈ | -238.2 m ≈ | -228.4 m ≈ | -175.6 m ≈ | -126.4 m ≈ | SEC (XBRL)· 05 Mar 2026derived |
| Investing cash flow | 122.8 m | -406.6 m | -11.9 m | 190.9 m | 103.4 m | -15.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Financing cash flow | 200.2 m | 195.3 m | -28.8 m | -35.0 m | 92.7 m | 116.8 m | SEC (XBRL)· 05 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 509.0 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -112.6% | 59 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 14.8% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.9x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 2.9x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -49.1% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial59/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
REGENXBIO Inc. (RGNX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 170.4 m USD in 2025; YoY growth 104.5%; net margin -112.6%; ROE -137.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 14.8%
- Current ratio: 2.9x
What contradicts it
- Interest coverage: -3.9x
- FCF yield: -49.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| ARGXArgenx Se | 57.6 bn | 47.6 | 20.2% | — | +254.4% | +2% / +107% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| TECHBio-Techne Corp | 11.4 bn | 62.7 | 9.0% | 15.0% | −0.4% | +13% / +16% |
| QGENQiagen N.V. | 11.0 bn | 26.2 | 11.6% | 20.3% | +5.7% | +6% / +20% |
| IBRXImmunitybio, Inc. | 9.5 bn | — | — | -598.6% | +668.3% | +278% / +143% |
| BEAMBeam Therapeutics Inc. | 2.9 bn | — | -11.3% | -73.9% | +120.0% | +10% / −1% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.4 bn | — | -48.7% | -697.1% | +26.9% | −16% / −43% |
| NVAXNovavax Inc | 1.8 bn | — | — | -59.9% | +64.7% | +51% / +94% |
| TSHATaysha Gene Therapies, Inc. | 1.4 bn | — | -47.1% | -2,728.0% | +17.3% | −8% / +148% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| GLUEMonte Rosa Therapeutics, Inc. | 923.1 m | — | -42.7% | -560.9% | +63.5% | −33% / +249% |
| PRMEPrime Medicine, Inc. | 901.4 m | — | -373.3% | -4,056.4% | +55.3% | +30% / −32% |
| SLDBSolid Biosciences Inc. | 727.7 m | — | -76.9% | — | −40.6% | +20% / +131% |
| RGNXREGENXBIO Inc. | 509.0 m | — | -137.6% | -112.6% | +104.5% | −33% / −50% |
| CCCCC4 Therapeutics, Inc. | 383.8 m | — | -48.1% | -289.4% | +1.0% | +15% / +91% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| AGENAgenus Inc | 313.8 m | 2.6 | — | 69.3% | +10.4% | +53% / −55% |
| SABSSab Biotherapeutics, Inc. | 289.3 m | — | -11.3% | — | −100.0% | −19% / −67% |
| FATEFate Therapeutics Inc | 250.4 m | — | -60.7% | -1,941.1% | −51.2% | +83% / −16% |
1- and 3-year price returns: for RGNX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and moreSTAT News · 24 Aug 2026 · EN
- STAT+: FDA pauses Regenxbio gene therapy trial again for safety concernsSTAT News · 24 Aug 2026 · EN
- AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock MoversBloomberg Markets · 22 Jun 2026 · EN
The latest news item in our archive is from 24 Aug 2026; the newest SEC filing is from 16 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report16 Oct 2026Departure or appointment of officers
- Current report23 Sept 2026Material agreement
- Current report25 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Current report24 Aug 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report20 Jul 2026Other events · Financial statements and exhibits
- Current report29 Jun 2026Other events · Financial statements and exhibits
- Current report03 Jun 2026Shareholder vote · Other events
- Quarterly report14 May 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.